The efficacy of a herbal medicine (Mao-to) in combination with intravenous natural interferon-β for patients with chronic hepatitis C, genotype 1b and high viral load: a pilot study

Kainuma, Mosaburo; Ogata, Norio; Kogure, Toshiaki; Kohta, Kazufumi; Hattori, Naoko; Mitsuma, Tadamichi; Terasawa, Katsutoshi

doi:10.1078/09447110260571571

Cited by 13 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, 15 out of 45 patients achieved SVR. When patients with genotype 1b and high viral load have been treated with IFN‐β monotherapy, it has been reported that the SVR rate ranges 0–11% 12,21 . Thus, the present study indicates that the combination therapy of IFN‐β and ribavirin is more effective for elderly patients with HCV genotype 1b and high viral load compared with IFN‐β monotherapy.…”

Section: Discussionsupporting

confidence: 50%

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load

Arase¹,

Kawamura²,

Suzuki³

et al. 2012

Hepatology Research

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 50%

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load

Arase¹,

Kawamura²,

Suzuki³

et al. 2012

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…Moreover, IFN-beta could be given to elderly patients aged !70 years because of the mild side effects (10). However, IFN-beta monotherapy does not result in a satisfactory outcome in patients with genotype 1b and a high virus load (11,12). The combination therapy of IFN-beta and ribavirin has the possibility to show the strong effect for hepatitis C virus (HCV) and mild side effects originating from the treatment (13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C patients

Arase

Suzuki

et al. 2011

Intern. Med.

View full text Add to dashboard Cite

Objective The aim of this study was to evaluate the efficacy and safety of combination therapy of natural human interferon-beta and ribavirin for patients for whom prior interferon therapy was discontinued due to depression induced by interferon-alpha. Methods Inclusion criteria were as follows; 1) HCV-genotype 1b, 2) serum HCV RNA level of !100 KIU/mL, 3) stopping the prior interferon-alpha monotherapy or combination therapy of interferon-alpha and ribavirin due to the appearance of depression. A total of 14 were enrolled in this prospective cohort study. The treatment period of combination therapy was 48 weeks. Depression states, reflected by Beck depression inventories and Hamilton depression rating scale, were assessed during combination therapy. Nonparametric procedures were employed for the analysis of background features of the patients with sustained virological response (SVR) and without SVR. A p value of <0.05 was considered to indicate a significant difference. Results Five of 14 patients (37.5%) had SVR by the intention to treat analysis. The SVR rate in patients who showed negative HCV RNA at 12 and 24 weeks after the initiation of combination therapy was 100% (4/4) and 83.3% (5/6), respectively. All of the patients continued the combination therapy owing to disappearance of severely adverse events contained the exacerbation of depression. Combination therapy did not yield a statistical difference in Beck depression inventories and Hamilton depression rating scale. Conclusion The combination therapy of IFN-beta and ribavirin is a possible therapy selection for the patients for whom interferon therapy was discontinued due to depression induced by interferon-alpha.

show abstract

“…However, some researchers have reported that IFN monotherapy does not result in a satisfactory outcome in patients with genotype 1b and a high virus load in the general population (23,24). Even though most rapid virological response (RVR) cases achieve a sustained virological response (SVR), relapse was observed in the present case.…”

Section: Discussionmentioning

confidence: 43%

Treatment of a Serotype-1 Hepatitis C Virus Infection Using Interferon-Beta in a Patient with a High RNA Titer Who Had Been Receiving Long-Term Hemodialysis Therapy

Otsubo

Kawata²,

Takasaki³

et al. 2011

Intern. Med.

View full text Add to dashboard Cite

A serotype-1 hepatitis C virus (HCV) infection in a 67-year-old hemodialysis patient was treated using interferon (IFN)-beta. Although the patient had a high RNA titer (5.1 log IU/mL) and had been receiving longterm hemodialysis therapy (30 years), the initial 4-week IFN-beta administration enabled a rapid virological response without any major adverse effects. However, the final outcome after 24 weeks of IFN beta treatment was classified as unchanged based on the criteria of the Conference on Intractable Hepatitis. Here, we describe our experience treating HCV infection using IFN-beta and discuss the indications for such therapy.

show abstract

The efficacy of a herbal medicine (Mao-to) in combination with intravenous natural interferon-β for patients with chronic hepatitis C, genotype 1b and high viral load: a pilot study

Cited by 13 publications

References 24 publications

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load

Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C patients

Treatment of a Serotype-1 Hepatitis C Virus Infection Using Interferon-Beta in a Patient with a High RNA Titer Who Had Been Receiving Long-Term Hemodialysis Therapy

Contact Info

Product

Resources

About